This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oxygen Biotherapeutics Reports Financial Results For Fiscal Year 2013

Research and development (R&D) expenses for the year ended April 30, 2013 declined less than one percent to $2,455,816 compared with $2,462,638 in the prior year.

During the year ended April 30, 2013, interest expense was approximately $4.2 million compared to approximately $7.4 million in the prior year. In the current year we recognized non-cash interest expense related to the fair-value adjustments to our Series A preferred stock, dividends paid on our Series A preferred stock and quarterly interest accrued on our outstanding convertible notes payable.

Other expense decreased approximately $92,000 for the year ended April 30, 2013 compared to the prior year, primarily due to the write off of receivables from Glucometrics, Inc, or Glucometrics in the prior year. Glucometrics previously held license rights for the use of our patents related to glucose monitoring technology.

For the fiscal year ended April 30, 2013, we reported a net loss of $10,373,871, or $6.68 per diluted share compared to a net loss of $15,712,410, or $14.07 per diluted share, in the prior year.

We ended the fiscal year with cash and cash equivalents totaling $783,528 compared with $1,879,872, in the prior year.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte ® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte ® line of skin care cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor Cosmetics of Switzerland.

Financial Tables Follow

The accompanying notes found in the Company’s Form 10-K filed with the SEC on June 26, 2013 are an integral part of these Financial Statements.


(a development stage enterprise)



April 30, 2013
April 30, 2012
Current assets
Cash and cash equivalents $ 783,528 $ 1,879,872
Accounts receivable 445,237 13,385
Government grant receivable 96,226 35,650
Inventory 99,204 83,370
Prepaid expenses 247,646 455,946
Other current assets   170,410     162,809  
Total current assets 1,842,251 2,631,032
Property and equipment, net 205,389 293,606
Debt issuance costs, net 150,043 278,659
Intangible assets, net 924,698 872,971
Other assets   58,262     65,666  
Total assets $ 3,180,643   $ 4,141,934  
Current liabilities
Accounts payable $ 977,162 $ 542,809
Accrued liabilities 874,876 1,273,837
Convertible preferred stock - 1,247,266
Current portion of notes payable, net   57,539     62,958  
Total current liabilities 1,909,577 3,126,870
Other liabilities 54,660 -
Long-term portion of notes payable, net   2,994,442     1,361,110  
Total liabilities 4,958,679 4,487,980
Commitments and contingencies; see Note J.
Stockholders' deficit

Preferred stock, undesignated, authorized 9,990,400 shares; issued 2,100;

outstanding 987 and 0, respectively; see Note E and Note H.
1 -

Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued

and outstanding 1,930,078 and 1,470,890, respectively
193 2,942
Additional paid-in capital 115,265,854 107,279,296
Deficit accumulated during the development stage   (117,044,084 )   (107,628,284 )
Total stockholders’ deficit   (1,778,036 )   (346,046 )
Total liabilities and stockholders' deficit $ 3,180,643   $ 4,141,934  


(a development stage enterprise)



Year ended April 30,

Period from May 26,

1967 (Inception) to

April 30, 2013
2013   2012
Product revenue $ 562,937 $ 92,683 $ 100,519
Cost of sales   352,579     43,111     51,253  
Net product revenue 210,358 49,572 49,266
Government grant revenue   1,455,871     1,141,356     314,515  
Total net revenue 1,666,229 1,190,928 363,781
Operating expenses
Selling, general, and administrative 50,585,212 3,676,145 6,091,806
Research and development 24,531,128 2,455,816 2,462,638
Restructuring expense 220,715 220,715 -
Loss on impairment of long-lived assets   390,970     27,279     29,534  
Total operating expenses 75,728,025 6,379,955 8,583,978
Net operating loss 74,061,796 5,189,027 8,220,197
Interest expense 43,962,019 4,238,456 7,412,054
Loss on extinguishment of debt 250,097 - -
Other (income) expense   (1,229,828 )   (11,683 )   80,159  
Net loss $ 117,044,084   $ 9,415,800   $ 15,712,410  
Preferred stock dividend   958,071     958,071     -  
Net loss attributable to common stockholders $ 118,002,155   $ 10,373,871   $ 15,712,410  
Net loss per share, basic $ (6.29 ) $ (12.12 )
Weighted average number of common shares outstanding, basic 1,650,280 1,296,414
Net loss per share, diluted $ (6.68 ) $ (14.07 )
Weighted average number of common shares outstanding, diluted 1,759,025 1,387,621

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in annual report on Form 10-K filed on June 26, 2013 as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs